November 2, 2023 – cTRL Therapeutics (“cTRL”), a FACIT co-founded and financed company developing novel tumour cell therapies for patients living with cancer, welcomes industry veteran Derrell D. Porter, M.D., as Chief Executive Officer.
Category: FACIT Features
FACIT applauds quizartinib approval: a success for leukemia patients and Canadian cancer research translation
July 24, 2023 – The U.S. FDA announced the approval of quizartinib, an important new therapy for patients with leukemia. This global effort to impact patients in need is to be celebrated while recognizing the contributions from across the Canadian health R&D ecosystem to reach this significant milestone that will now make a difference for patients.
FACIT founded Turnstone Biologics debuts on Nasdaq market
July 21, 2023 – FACIT congratulates Turnstone Biologics on the announcement of their upsized initial public offering (IPO) and debut on the Nasdaq market.
Read More from FACIT founded Turnstone Biologics debuts on Nasdaq market
FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies
April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.
CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.